2022 Q3 Form 10-Q Financial Statement

#000149315222033843 Filed on November 28, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2021 Q3

Balance Sheet

Concept 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $67.33K
YoY Change -100.0%
Cash & Equivalents $67.33K
Short-Term Investments
Other Short-Term Assets $40.00K
YoY Change
Inventory $24.00K
Prepaid Expenses
Receivables $54.25K
Other Receivables $89.51K
Total Short-Term Assets $167.8K $381.0K
YoY Change -55.97%
LONG-TERM ASSETS
Property, Plant & Equipment $501.8K $417.6K
YoY Change 20.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.970M $1.919M
YoY Change 2.67%
TOTAL ASSETS
Total Short-Term Assets $167.8K $381.0K
Total Long-Term Assets $1.970M $1.919M
Total Assets $2.137M $2.300M
YoY Change -7.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $981.3K $112.5K
YoY Change 772.42%
Accrued Expenses $893.4K $441.3K
YoY Change 102.45%
Deferred Revenue
YoY Change
Short-Term Debt $1.398M $5.711M
YoY Change -75.52%
Long-Term Debt Due $4.320M
YoY Change
Total Short-Term Liabilities $7.876M $6.311M
YoY Change 24.78%
LONG-TERM LIABILITIES
Long-Term Debt $378.5K $148.6K
YoY Change 154.65%
Other Long-Term Liabilities $197.2K
YoY Change
Total Long-Term Liabilities $575.7K $148.6K
YoY Change 287.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.876M $6.311M
Total Long-Term Liabilities $575.7K $148.6K
Total Liabilities $8.451M $6.460M
YoY Change 30.82%
SHAREHOLDERS EQUITY
Retained Earnings -$12.23M
YoY Change
Common Stock $231.5K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.314M -$4.161M
YoY Change
Total Liabilities & Shareholders Equity $2.137M $2.300M
YoY Change -7.05%

Cashflow Statement

Concept 2022 Q3 2021 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 OMWS Secured Debts
SecuredDebts
usd
CY2022Q3 us-gaap Secured Debt
SecuredDebt
usd
CY2022Q1 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
usd
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
OMWS Bad Debt Expense
BadDebtExpense
usd
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
usd
OMWS Increase Decrease In Deposit Liability
IncreaseDecreaseInDepositLiability
usd
CY2022Q3 us-gaap Deposit Liability Current
DepositLiabilityCurrent
usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
usd
OMWS Payment For Subscriptions Receivable
PaymentForSubscriptionsReceivable
usd
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
OMWS Payment For Subscriptions Receivable
PaymentForSubscriptionsReceivable
usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
usd
OMWS Product Warranty Expenses
ProductWarrantyExpenses
usd
dei Entity Central Index Key
EntityCentralIndexKey
0001676852
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
OMWS Product Warranty Expenses
ProductWarrantyExpenses
usd
CY2022Q3 OMWS Product Warranty Expenses
ProductWarrantyExpenses
usd
CY2021Q3 OMWS Product Warranty Expenses
ProductWarrantyExpenses
usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
usd
CY2021Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
usd
OMWS Other Selling General And Administrative Expense Related Party
OtherSellingGeneralAndAdministrativeExpenseRelatedParty
usd
OMWS Other Selling General And Administrative Expense Related Party
OtherSellingGeneralAndAdministrativeExpenseRelatedParty
usd
CY2022Q3 OMWS Other Selling General And Administrative Expense Related Party
OtherSellingGeneralAndAdministrativeExpenseRelatedParty
usd
CY2021Q3 OMWS Other Selling General And Administrative Expense Related Party
OtherSellingGeneralAndAdministrativeExpenseRelatedParty
usd
OMWS Consulting Expense
ConsultingExpense
usd
CY2021Q3 OMWS Consulting Expense
ConsultingExpense
usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
usd
CY2021Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
usd
OMWS Royalty Expense Income
RoyaltyExpenseIncome
usd
CY2021Q3 OMWS Royalty Expense Income
RoyaltyExpenseIncome
usd
OMWS License Royalties
LicenseRoyalties
usd
OMWS License Royalties
LicenseRoyalties
usd
CY2022Q3 OMWS License Royalties
LicenseRoyalties
usd
CY2021Q3 OMWS License Royalties
LicenseRoyalties
usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
OMWS Gain On Ppp Loan Forgiven
GainOnPppLoanForgiven
usd
CY2022Q3 OMWS Gain On Ppp Loan Forgiven
GainOnPppLoanForgiven
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2022Q2 OMWS Reclass Par Value Of Shares And Shares Outstanding
ReclassParValueOfSharesAndSharesOutstanding
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
usd
OMWS Amortization Of Warrants
AmortizationOfWarrants
usd
OMWS Amortization Of Warrants
AmortizationOfWarrants
usd
OMWS Discount On Notes
DiscountOnNotes
usd
OMWS Discount On Notes
DiscountOnNotes
usd
OMWS Royalty On Sales
RoyaltyOnSales
usd
OMWS Finance Costs Related To Note Payable
FinanceCostsRelatedToNotePayable
usd
OMWS Finance Costs Related To Note Payable
FinanceCostsRelatedToNotePayable
usd
OMWS Finance Costs Paid In Stock
FinanceCostsPaidInStock
usd
OMWS Finance Costs Paid In Stock
FinanceCostsPaidInStock
usd
OMWS Gain Loss On Ppp Loan Forgiven
GainLossOnPppLoanForgiven
usd
OMWS Rent Payments On Lease Liability
RentPaymentsOnLeaseLiability
usd
OMWS Bad Debt Expense
BadDebtExpense
usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
usd
CY2021Q3 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Before Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation
usd
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
usd
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
usd
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-211986
dei Entity Registrant Name
EntityRegistrantName
OMNIA WELLNESS INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1291924
dei Entity Address Address Line1
EntityAddressAddressLine1
999 18th Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 3000
dei Entity Address City Or Town
EntityAddressCityOrTown
Denver
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80202
dei City Area Code
CityAreaCode
(888)
dei Local Phone Number
LocalPhoneNumber
320-5711
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
231505146 shares
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1894 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
54251 usd
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
118349 usd
CY2022Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
89505 usd
CY2022Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
91380 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
24000 usd
CY2022Q1 us-gaap Inventory Net
InventoryNet
24000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
167756 usd
CY2022Q1 us-gaap Assets Current
AssetsCurrent
235623 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
501778 usd
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
515113 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1350850 usd
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1450900 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
117098 usd
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
160197 usd
CY2022Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
1969726 usd
CY2022Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
2126210 usd
CY2022Q3 us-gaap Assets
Assets
2137482 usd
CY2022Q1 us-gaap Assets
Assets
2361833 usd
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
981301 usd
CY2022Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
562213 usd
CY2022Q1 us-gaap Deposit Liability Current
DepositLiabilityCurrent
8002 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
893443 usd
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
615261 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
101465 usd
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
99464 usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
25667 usd
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
25667 usd
CY2022Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
155289 usd
CY2022Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
143817 usd
CY2022Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
1852735 usd
CY2022Q1 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
1102735 usd
CY2022Q3 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
1792566 usd
CY2022Q1 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
1765219 usd
CY2022Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
29970 usd
CY2022Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
29970 usd
CY2022Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1368193 usd
CY2022Q1 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1229443 usd
CY2022Q3 OMWS Secured Debts
SecuredDebts
675000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7875629 usd
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5581791 usd
CY2022Q3 OMWS Due To Related Party Noncurrent
DueToRelatedPartyNoncurrent
163239 usd
CY2022Q1 OMWS Due To Related Party Noncurrent
DueToRelatedPartyNoncurrent
143239 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
33997 usd
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
80099 usd
CY2022Q1 us-gaap Secured Debt
SecuredDebt
675000 usd
CY2022Q3 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
141920 usd
CY2022Q1 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
891920 usd
CY2022Q3 OMWS Nonconvertible Notes Non Related
NonconvertibleNotesNonRelated
166571 usd
CY2022Q1 OMWS Nonconvertible Notes Non Related
NonconvertibleNotesNonRelated
189918 usd
CY2022Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
70000 usd
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
575727 usd
CY2022Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1980176 usd
CY2022Q3 us-gaap Liabilities
Liabilities
8451356 usd
CY2022Q1 us-gaap Liabilities
Liabilities
7561967 usd
CY2022Q3 OMWS Stock Payable
StockPayable
230367 usd
CY2022Q1 OMWS Stock Payable
StockPayable
642867 usd
CY2022Q3 OMWS Stock Reserve
StockReserve
412500 usd
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
150000000 shares
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
150000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
231505146 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
231505146 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
232222818 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
232222818 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
231505 usd
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
232223 usd
CY2022Q3 OMWS Common Stock Subscribed Par Or Stated Value Per Share
CommonStockSubscribedParOrStatedValuePerShare
0.001
CY2022Q1 OMWS Common Stock Subscribed Par Or Stated Value Per Share
CommonStockSubscribedParOrStatedValuePerShare
0.001
CY2022Q3 OMWS Common Stock Subscribed Shares Outstanding
CommonStockSubscribedSharesOutstanding
2500000 shares
CY2022Q1 OMWS Common Stock Subscribed Shares Outstanding
CommonStockSubscribedSharesOutstanding
0 shares
CY2022Q3 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
2500 usd
CY2022Q1 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
2500 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5445438 usd
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5344318 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12226184 usd
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11012042 usd
CY2022Q3 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
410000 usd
CY2022Q1 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
410000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-6313874 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-5200134 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2137482 usd
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2361833 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
162092 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94931 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28446 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
57809 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
98500 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
15010 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
77534 usd
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8477 usd
us-gaap Cost Of Revenue
CostOfRevenue
98500 usd
us-gaap Cost Of Revenue
CostOfRevenue
15010 usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
77534 usd
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
8477 usd
us-gaap Gross Profit
GrossProfit
63592 usd
us-gaap Gross Profit
GrossProfit
79921 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
-49088 usd
CY2021Q3 us-gaap Gross Profit
GrossProfit
49332 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
190783 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
143036 usd
us-gaap Professional Fees
ProfessionalFees
356002 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1536678 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
95448 usd
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
72557 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
6000 usd
CY2022Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
6000 usd
us-gaap Professional Fees
ProfessionalFees
85559 usd
CY2022Q3 us-gaap Professional Fees
ProfessionalFees
83780 usd
CY2021Q3 us-gaap Professional Fees
ProfessionalFees
255048 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
219501 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
84104 usd
CY2022Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
88230 usd
CY2021Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
58937 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
20779 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
30920 usd
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2220 usd
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
30544 usd
OMWS Consulting Expense
ConsultingExpense
44180 usd
CY2022Q3 OMWS Consulting Expense
ConsultingExpense
27239 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
91000 usd
CY2022Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
45000 usd
OMWS Royalty Expense Income
RoyaltyExpenseIncome
-11472 usd
CY2022Q3 OMWS Royalty Expense Income
RoyaltyExpenseIncome
3805 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
150096 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
68412 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
64776 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9184 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48200 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
732000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
397500 usd
us-gaap Operating Expenses
OperatingExpenses
867570 usd
us-gaap Operating Expenses
OperatingExpenses
1414474 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
408889 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
823770 usd
OMWS Gain On Ppp Loan Forgiven
GainOnPppLoanForgiven
443873 usd
CY2021Q3 OMWS Gain On Ppp Loan Forgiven
GainOnPppLoanForgiven
146959 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
410164 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1045638 usd
CY2022Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
176640 usd
CY2021Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
918807 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-410164 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-601765 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-176640 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-771848 usd
us-gaap Net Income Loss
NetIncomeLoss
-1214142 usd
us-gaap Net Income Loss
NetIncomeLoss
-1936318 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-634617 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1546286 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
231507112 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
224213846 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
231509068 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
224213846 shares
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-3408641 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
430123 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-390032 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-3368550 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
754291 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1546286 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-4160545 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-5200134 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
77561 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-579526 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-5702099 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-5702099 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
22841 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-634617 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-634617 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-6313874 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-6313874 usd
us-gaap Net Income Loss
NetIncomeLoss
-1214142 usd
us-gaap Net Income Loss
NetIncomeLoss
-1936318 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
147685 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
143576 usd
OMWS Convertibles Notes Convertible Beneficial Conversion Feature
ConvertiblesNotesConvertibleBeneficialConversionFeature
100402 usd
OMWS Convertibles Notes Convertible Beneficial Conversion Feature
ConvertiblesNotesConvertibleBeneficialConversionFeature
771576 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
43099 usd
OMWS Royalty On Sales
RoyaltyOnSales
11472 usd
OMWS Gain Loss On Ppp Loan Forgiven
GainLossOnPppLoanForgiven
440266 usd
OMWS Rent Payments On Lease Liability
RentPaymentsOnLeaseLiability
44101 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-64098 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
72418 usd
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-1875 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
24000 usd
OMWS Increase Decrease In Deposit Liability
IncreaseDecreaseInDepositLiability
8002 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
449088 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7771 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
278182 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
13401 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-170344 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
212750 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
34300 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
146750 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-34300 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-146750 usd
OMWS Proceeds From Advances
ProceedsFromAdvances
20000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
1309154 usd
OMWS Payments On Advances
PaymentsOnAdvances
30000 usd
OMWS Payments For Decrease In Stock Subscription Payable
PaymentsForDecreaseInStockSubscriptionPayable
412500 usd
OMWS Proceeds From Increase In Stock Reserve
ProceedsFromIncreaseInStockReserve
412500 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
718 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
-718 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
412839 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
202750 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1721993 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1894 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
38565 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1894 usd
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28761 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
67326 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_801_eus-gaap--NatureOfOperations_zgmZHVgYrOn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Note 1 <span id="xdx_822_zUlEHaVgJhnc">Nature of Operations</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Omnia Wellness Inc. (the “Company”) was incorporated as a Nevada corporation on <span id="xdx_902_edei--EntityIncorporationDateOfIncorporation_c20220401__20220930_zhLlIN5ef2Jh" title="Entity incorporation, date of incorporation">March 2, 2016</span>, by the filing of articles of incorporation with the Secretary of State of the State of <span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20220401__20220930_zTrCrCWwX1W7" title="Entity incorporation, state or country code">Nevada</span> under the name Glolex, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--EquityMethodInvestmentDescriptionOfPrincipalActivities_c20220401__20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MaksimCharniakMember_zdFDn6ULBWl4" title="Equity method investment description">On June 25, 2019, Maksim Charniak, the Company’s then sole executive officer and director and the owner of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesStockSplits_c20190624__20190625__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MrAmerSamadMember_zq3M6MNDkIBl" title="Stock split shares">3,000,000</span> shares (pre- stock split) of the Company’s common stock, sold all his shares of common stock of the Company to Amer Samad, resulting in a change of control of the Company. As part of that transaction, Mr. Charniak resigned from all of his officer and director positions, and Mr. Samad was appointed as the Chief Executive Officer, President, Chief Financial Officer and Secretary of the Company, and was appointed to the Board of Directors of the Company. Mr. Samad also purchased 1,167,937 shares (pre-stock split) of the Company’s common stock in a series of private transactions, resulting in Mr. Samad owning 4,167,937 shares (pre-stock split) of the Company’s common stock, or approximately <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20190625__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MrAmerSamadMember_zYq2bmCjikki" title="Ownership percentage">95.6</span>% of the issued and outstanding common stock of the Company.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 5, 2020, the Company filed Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada to, among other things, (i) increase the Company’s authorized shares of common stock from <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20200304_zYNMxwXkLvRb" title="Common stock, shares authorized">75,000,000</span> to <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20200305_zkDRxXsvcll5" title="Common stock, shares authorized">100,000,000</span>, (ii) create and authorize <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20200305__srt--StatementScenarioAxis__custom--BlankCheckMember_zqBrB67ouOa5" title="Preferred stock authorized">10,000,000</span> shares of “blank check” preferred stock, and (iii) effect a <span id="xdx_908_eus-gaap--StockholdersEquityNoteStockSplit_c20200303__20200305_z1Ia8OqZYN1j" title="Forward stock split">12.6374:1</span> forward stock split of the common stock. In addition, on March 16, 2020, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada to change the name of the Company from Glolex Inc. to Omnia Wellness Inc. On April 15, 2020, the stock of the Company began trading on the OTC Pink market under the symbol “OMWS”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 17, 2020, the Company entered into a Share Exchange and Reorganization Agreement (the “Exchange Agreement”) with Omnia Wellness Corporation (formerly known as Bed Therapies Inc.), a Texas corporation (“Omnia Corp.”), and the beneficial stockholders of Omnia Corp. to acquire <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20200417__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BedTherapiesIncMember_zlyvUWGUHQ95" title="Ownership percentage">100</span>% of the issued and outstanding shares of capital stock of Omnia Corp. The transactions contemplated by the Exchange Agreement were consummated on January 5, 2021, and, pursuant to the terms of the Exchange Agreement, among other things, all outstanding shares of common stock of Omnia Corp., no par value, or the Omnia Corp. Shares, were exchanged for shares of the Company’s common stock, par value $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20200417__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BedTherapiesIncMember_zoVvTfRZiGf1" title="Common stock, par value">0.001</span> per share, based on the exchange ratio of one share of the Company’s common stock for every one Omnia Corp. Share. The Company refers herein to the transactions contemplated by the Exchange Agreement, collectively, as the Acquisition. <span id="xdx_903_eus-gaap--StockholdersEquityNoteStockSplit_c20210404__20210406__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BedTherapiesIncMember_zFbNEAsBm4f8" title="Forward stock split description">Accordingly, the Company acquired 100% of Omnia Corp. in exchange for the issuance of 10,000,000 (not adjusted to reflect the Company’s 15:1 forward stock split on April 6, 2021) shares of the Company’s common stock and Omnia Corp. became the Company’s wholly owned subsidiary. As of the closing of the Acquisition (the “Closing”), Mr. Samad, resigned as an officer and director of the Company and agreed to cancel <span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_c20200416__20200417__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BedTherapiesIncMember__srt--TitleOfIndividualAxis__custom--MrAmerSamadMember_zCvzOz7isHW8" title="Cancellation of stock split">52,656,888</span></span> (pre-stock split) shares of the Company’s common stock owned beneficially and of record by him as part of the conditions to Closing, which were cancelled immediately following the Closing. The Company also issued an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockSplits_c20210104__20210105__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BedTherapiesIncMember_zT66TGEC1Zpj" title="Stock issued during period shares stock splits">1,269,665</span> (pre-stock split) shares of common stock on January 5, 2021, as a result of the conversion in accordance with their terms of outstanding convertible promissory notes in the aggregate principal amount of approximately $<span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20200416__20200417__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BedTherapiesIncMember_zDJVV05CQv7k" title="Debt conversion, converted instrument, amount">539,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of immediately prior to the closing of the Acquisition, the Company entered into an Assignment and Assumption Agreement with RZI Consulting LLC (the “Assignment Agreement”), pursuant to which RZI Consulting LLC assumed substantially all of the Company’s remaining assets and liabilities through the closing of the Acquisition. Accordingly, as of the closing of the Acquisition, the Company had no assets or liabilities (other than relating to general and administrative expenses).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the Acquisition, the Company, through its wholly owned subsidiary Omnia Corp., now develops and markets products for wellness and physical therapy markets, using patented dry-hydro therapy equipment that the Company plans to offer and sell in medical and fitness markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 6, 2021, <span id="xdx_909_eus-gaap--StockholdersEquityNoteStockSplit_c20210404__20210406__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--BedTherapiesIncMember__srt--TitleOfIndividualAxis__custom--MrAmerSamadMember_zaQdQpmmp74d" title="Stockholders equity description">the Company filed a Certificate of Change with the Secretary of State of the State of Nevada to (i) increase the Company’s authorized shares of common stock from <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20210406__srt--RangeAxis__srt--MinimumMember_z8f6rd6SIv16" title="Common stock, shares authorized">100,000,000</span> to <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20210406__srt--RangeAxis__srt--MaximumMember_ztkU7AsbxA4j" title="Common stock, shares authorized">1,500,000,000</span>, (ii) increase the Company’s authorized shares of “blank check” preferred stock from <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20210406__srt--RangeAxis__srt--MinimumMember_zRzw20wuMsgb" title="Preferred stock authorized">10,000,000</span> to <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20210406__srt--RangeAxis__srt--MaximumMember_z9PO49G1DZha" title="Preferred stock authorized">150,000,000</span>, and (iii) effect a 1:15 forward stock split of the common stock.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s principal executive office is located at 999 18<sup>th</sup> St., Suite 3000, Denver, CO 80202, and its telephone number is 303-325-3738. The Company’s website address is www.omniawellness.com.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2020 the World Health Organization declared COVID-19 a pandemic. The Company is still assessing the impact COVID-19 may have on its business, but there can be no assurance that this analysis will enable the Company to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally. The extent to which the COVID-19 pandemic and global efforts to contain its spread will impact the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, and include the duration, severity and scope of the pandemic and the actions taken to contain or treat the COVID-19 pandemic.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2016-03-02
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q1 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
12.6374:1
us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de- recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.
CY2019Q2 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P10Y
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100050 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_849_eus-gaap--UseOfEstimates_zUAn5v8AX5of" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zXb6z61wEhEl">Accounting Estimates</span> </i></b>- The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and the accompanying notes. Such estimates and assumptions impact, among others, the following: the allowance for doubtful accounts, determination of impairment on investments and determination of recoverability of deferred tax assets. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zNKmbSKSHQbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zN4ZurRzMeA1">Risks and Uncertainties</span></i></b> - The Company’s operations may be subject to significant risk and uncertainties including financial, operational, regulatory, and other risks associated with a start-up company, including the potential risk of business failure. See Note 3 regarding going concern matters.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
231505146 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
224227107 shares
CY2022Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
54251 usd
CY2021Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
66950 usd
us-gaap Depreciation
Depreciation
147684 usd
us-gaap Depreciation
Depreciation
143036 usd
CY2019Q2 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
350000 usd
CY2019Q2 us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
1000 usd
CY2019Q4 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
200000 usd
CY2022Q3 us-gaap Advances On Inventory Purchases
AdvancesOnInventoryPurchases
0 usd
CY2021Q3 us-gaap Advances On Inventory Purchases
AdvancesOnInventoryPurchases
40000 usd
CY2022Q3 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation
241854 usd
CY2021Q3 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation
169230 usd
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P10Y
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
650150 usd
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
500075 usd
CY2020Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1450000 usd
CY2022Q3 OMWS Royalty Liability
RoyaltyLiability
32808 usd
CY2022Q3 OMWS Monthly Sales Percent
MonthlySalesPercent
0.05 pure
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
892004 usd
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
669304 usd
CY2022Q3 OMWS Property Plant And Equipment And Intangible Assets Net
PropertyPlantAndEquipmentAndIntangibleAssetsNet
1852628 usd
CY2021Q3 OMWS Property Plant And Equipment And Intangible Assets Net
PropertyPlantAndEquipmentAndIntangibleAssetsNet
1918527 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100050 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
135462 usd
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
Our assessment is based on (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period and (3) whether we have the right to direct the use of the asset. Leases are classified as either finance leases or operating leases.
CY2022Q3 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Before Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation
147363 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
117098 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
101465 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
33997 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
135462 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
44101 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
8080 usd
CY2021 us-gaap Short Term Debt Interest Rate Increase
ShortTermDebtInterestRateIncrease
1.0 pure
CY2021Q2 OMWS Gain On Ppp Loan Forgiven
GainOnPppLoanForgiven
294066 usd
CY2021Q3 OMWS Gain On Ppp Loan Forgiven
GainOnPppLoanForgiven
146200 usd
CY2021Q4 OMWS Gain On Ppp Loan Forgiven
GainOnPppLoanForgiven
148625 usd
CY2022Q1 OMWS Gain On Ppp Loan Forgiven
GainOnPppLoanForgiven
593546 usd
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
513827 usd
us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
1014478 usd
us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
771576 usd
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 usd
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 usd
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0 usd
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0 usd
CY2022Q3 us-gaap Area Of Land
AreaOfLand
200 sqft

Files In Submission

Name View Source Status
0001493152-22-033843-index-headers.html Edgar Link pending
0001493152-22-033843-index.html Edgar Link pending
0001493152-22-033843.txt Edgar Link pending
0001493152-22-033843-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
omws-20220930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
omws-20220930_cal.xml Edgar Link unprocessable
omws-20220930_pre.xml Edgar Link unprocessable
omws-20220930_def.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
omws-20220930_lab.xml Edgar Link unprocessable